IP Library Granted Patent US 11,479,615
Granted Patent B2
US 11,479,615 · App. 16/864,583 · Granted Oct 25, 2022

Anti-coagulation factor XI antibodies

Inventors: Zhu Chen (Warren, NJ); Kenneth Ellsworth (Cranbury, NJ); James Milligan (New Egypt, NJ); Elizabeth Oldham (Santa Clara, CA); Dietmar Seiffert (Lawrence Township, NJ); Bianka Prinz (Lebanon, NH)
Assignees: Merck Sharp & Dohme LLC; Adimab, LLC
C07K16/36A61K39/3955A61K2039/505A61K2039/58C07K2317/75C07K2317/76C07K2317/90C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,479,615
App. No.
16/864,583
Granted
Oct 25, 2022
Kind
B2
Abstract

Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.

Claims (26)

1. An antibody or antigen binding fragment comprising:

(i) at least the six complimentary determining regions (CDRs) of an anti-FXI antibody of the αFXI-18611 family,

wherein the antibody of the αFXI-18611 family comprises an HC having the amino acid sequence shown in SEQ ID NO:37 or 39 and an LC having the amino acid sequence shown in SEQ ID NO:26.

2. The antibody or antigen binding fragment of claim 1 , wherein the six CDRs of the αFXI-18611 family comprise:

HC CDR1 having the amino acid sequence set forth in SEQ ID NO:1, HC CDR2 having the amino acid sequence set forth in SEQ ID NO:2, and HC CDR3 having the amino acid sequence set forth in SEQ ID NO:4, LC-CDR1 having the amino acid sequence set forth in SEQ ID NO:5, LC CDR2 having the amino acid sequence set forth in SEQ ID NO:6, and LC CDR3 having the amino acid sequence set forth in SEQ ID NO:7.

3. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment comprises a HC variable domain comprising the amino acid sequence set forth in SEQ ID NO: 23 or 24 and a LC variable domain comprising the amino acid sequence set forth in SEQ ID NO:25.

4. The antibody or antigen binding fragment of any one of claim 1 , wherein the antibody comprises a HC constant domain comprising the amino acid sequence shown in SEQ ID NO:16, 17, 18, or 19.

5. The antibody or antigen binding fragment of any one of claim 1 , wherein the antibody comprises a LC constant domain comprising the amino acid sequence shown in SEQ ID NO:20.

6. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antibody fragment comprises:

(a) a heavy chain (HC) variable domain having the amino acid sequence shown in SEQ ID NO:23 and a light chain (LC) variable domain having the amino acid sequence shown in SEQ ID NO:25; or

(b) a heavy chain (HC) variable domain having the amino acid sequence shown in SEQ ID NO: 24 and a light chain (LC) variable domain having the amino acid sequence shown in SEQ ID NO:25.

7. The antibody or antigen binding fragment of claim 6 , wherein the antibody further comprises a HC constant domain comprising the amino acid sequence shown in SEQ ID NO:16, 17, 18, 19.

8. The antibody or antigen binding fragment of claim 6 , wherein the antibody further comprises a LC constant domain comprising the amino acid sequence shown in SEQ ID NO:20.

9. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment binds the apple 3 domain of coagulation factor XI (FXI) and inhibits activation of FXI and/or Factor XIa-mediated activation of Factor IX.

10. The antibody or antigen binding fragment of claim 1 , wherein the antibody comprises:

(a) an HC having a constant domain and a variable domain wherein the variable domain comprises a heavy chain comprising a heavy chain-complementary determining region (HC-CDR) 1 having the amino acid sequence shown in SEQ ID NO: 1, a HC-CDR 2 having the amino acid sequence shown in SEQ ID NO:2, and a HC-CDR 3 having the amino acid sequence shown in SEQ ID NO:4; and

(b) an LC having a constant domain and a variable domain wherein the variable domain comprises a light chain-complementary determining region (LC-CDR) 1 having the amino acid sequence shown in SEQ ID NO:5, a LC-CDR 2 having the amino acid sequence shown in SEQ ID NO:6, and a LC-CDR 3 having the amino acid sequence shown in SEQ ID NO:7.

11. The antibody or antigen binding fragment of claim 10 , wherein the antibody comprises an HC constant domain comprising the amino acid sequence shown in SEQ ID NO:16, 17, 18, or 19.

12. The antibody or antigen binding fragment of claim 10 , wherein the antibody comprises an LC constant domain comprising the amino acid sequence shown in SEQ ID NO:20.

13. The antibody or antigen binding fragment of claim 1 , wherein the antibody comprises:

an HC having the amino acid sequence shown in SEQ ID NO: 37, 39, 49, 51, 73, or 75; and

an LC having the amino acid sequence shown in SEQ ID NO:26.

14. A composition comprising the antibody or antigen binding fragment of claim 1 and a pharmaceutically acceptable carrier or diluent.

15. An antibody or antibody fragment comprising a heavy chain variable domain (V H ) comprising the amino acid sequence shown in SEQ ID NO: 23 or 24 and a light chain variable domain (V L ) comprising the amino acid sequence shown in SEQ ID NO:25.

16. The antibody or antibody fragment of claim 15 , wherein the antibody further comprises a heavy chain constant domain having the amino acid sequence shown in SEQ ID NO: 16 or 17 and a light chain constant domain having the amino acid sequence shown in SEQ ID NO:20.

17. A composition comprising the antibody or antibody fragment of claim 15 and a pharmaceutically acceptable carrier or diluent.

Assignments (4)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
MERGER Recorded Jun 21, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 060257/0852 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2022
From: CHEN, ZHU; ELLSWORTH, KENNETH; MILLIGAN, JAMES; OLDHAM, ELIZABETH; SEIFFERT, DIETMAR; GANTI, VAISHNAVI; TABRIZIFARD, MOHAMMAD
To: MERCK SHARP & DOHME CORP.
Reel/Frame 060226/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2022
From: PRINZ, BIANKA
To: ADIMAB, LLC
Reel/Frame 060226/0330 →
Continuity (3)
Division 15619620 · Jun 12, 2017
Provisional Application 62349888 · Jun 14, 2016
Related Publication 20200255542A1 · Aug 13, 2020
Cited By (1)
US 12,275,800